|
| Interactions: | Amoxycillin
Adverse Effect: loss of Sisomicin efficacy Clinical Management: Monitor patients for Sisomicin effectiveness.
Ampicillin
Adverse Effect: loss of Sisomicin efficacy Clinical Management: Monitor patients for Sisomicin effectiveness.
Atracurium
Adverse Effect: Enhanced and/or prolonged neuromuscular blockade which may lead to respiratory depression and paralysis Clinical Management: Avoid concomitant use of Sisomicin and Atracurium if possible. Concurrent use of Sisomicin and Atracurium requires close monitoring of the patients clinical condition, especially respiratory and oxygenation status. Calcium ions should be given in some form, particularly if large amounts of blood have been transfused. Edrophonium, neostigmine, or atropine may provide partial reversal of hypoventilation. As the block is reversible with time, artificial ventilation may be required and should be maintained until adequate respiration returns.
Bacampicillin
Adverse Effect: Loss of Sisomicin efficacy Clinical Management: Monitor patients for Sisomicin effectiveness.
Benzyl Penicillin
Adverse Effect: loss of Sisomicin efficacy Clinical Management: Monitor patients for Sisomicin effectiveness.
Carboplatin
Adverse Effect: ototoxicity Clinical Management: If clinically acceptable, an alternate antibiotic (a non-aminoglycoside) may be preferred.
Cefaclor
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Cefaclor could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Cefadroxil
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Cefadroxil could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Cefazolin
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Cefazolin could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Cefixime
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Cefixime could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Cefoperazone
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Cefoperazone could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Cefotaxime
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Cefotaxime could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Cefpirome
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Cefpirome could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Cefpodoxime
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Cefpodoxime could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Ceftazidime
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Ceftazidime could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Ceftizoxime
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Ceftizoxime could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Ceftriaxone
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Ceftriaxone could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Cefuroxime
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Cefuroxime could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Cephalexin
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Cephalexin could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Cephaloridine
Adverse Effect: an increased risk of nephrotoxicity Clinical Management: Coadministration of Sisomicin with Cephaloridine could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.
Frusemide
Adverse Effect: ototoxicity and/or nephrotoxicity Clinical Management: Consider periodic auditory testing for patients on high doses of either drug. Also monitor renal function.
Pancuronium
Adverse Effect: enhanced and/or prolonged neuromuscular blockade which may lead to respiratory depression and paralysis Clinical Management: Avoid concomitant use of Sisomicin and Pancuronium if possible. Concurrent use of Sisomicin and Pancuronium requires close monitoring of the patients clinical condition, especially respiratory and oxygenation status.
Penicillin V ( Phenoxymethyl )
Adverse Effect: loss of Sisomicin efficacy Clinical Management: Monitor patients for Sisomicin effectiveness.
Procaine Penicillin
Adverse Effect: Loss of Sisomicin efficacy Clinical Management: Monitor patients for Sisomicin effectiveness.
Vecuronium
Adverse Effect: Enhanced and/or prolonged neuromuscular blockade which may lead to respiratory depression and paralysis Clinical Management: Avoid concomitant use of Sisomicin and Vecuronium if possible. Concurrent use of Sisomicin and Vecuronium requires close monitoring of the patients clinical condition, especially respiratory and oxygenation status. Calcium ions should be given in some form, particularly if large amounts of blood have been transfused. Edrophonium, neostigmine, or atropine may provide partial reversal of hypoventilation. As the block is reversible with time, artificial ventilation may be required and should be maintained until adequate respiration returns.
|
|
|